CA19-9 elevation as an indication to start salvage treatment in surveillance after pancreatic cancer resection.
Pancreatology. 2019 Feb 1. pii: S1424-3903(19)30024-9. doi: 10.1016/j.pan.2019.01.023. [Epub ahead of print]
Li J1, Li Z2, Kan H3, Sun Z4, Xing J5, Cheng Y6, Bai C7.
BACKGROUND: CA19-9 is the most commonly used tumor marker in the diagnosis, prognosis and surveillance of pancreatic cancer. We hypothesized that CA19-9 elevation can be taken as an indication to start salvage treatment in surveillance after resection.
METHODS: From January 2014 and July 2017, 80 pancreatic cancer patients who underwent R0 surgical resection and received adjuvant chemotherapy were included.
RESULTS: Twenty-six (32.5%) patients started salvage treatment at the time of CA19-9 elevation without radiological evidence of recurrence. Fifty-four (67.5%) patients treated conventionally before recurrence was confirmed by radiological examinations. Sixty (75%) patients had CA19-9 elevation that preceded radiographic recurrence by about 3 months. In the intervention group, the median DFS (23.6 months vs. 12.1 months, P < 0.001) and OS (28.1 months vs. 20.7 months, P = 0.049) were significantly longer than those in the control group.
CONCLUSIONS: CA19-9 elevation could preceded recurrence confirmed by radiographic examinations in most patients. Tumor marker-guided salvage treatment can significantly prolong disease-free survival and overall survival in patients under surveillance after pancreatic cancer resection.